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ABSTRACT 
G protein-coupled receptors (GPCRs) are 
currently the target of more than 30% of the 
marketed medicines. However, there is an important 
medical need for ligands with improved 
pharmacological activities on validated drug targets. 
Moreover, most of these ligands remain poorly 
characterized, notably because of a lack of 
pharmacological tools. Thus, there is an important 
demand for innovative assays that can detect and 
drive the design of compounds with novel or 
improved pharmacological properties. In particular, 
a functional and screening-compatible GPCR-G 
protein interaction assay is still unavailable. Here, 
we report on a nanoluciferase-based 
complementation technique to detect ligands that 
promote a GPCR-G protein interaction. We 
demonstrate that our system can be used to profile 
compounds with regard to the G proteins they 
activate through a given GPCR. Furthermore, we 
established a proof of applicability of screening for 
distinct G proteins on dopamine receptor D2 whose 
differential coupling to Gαi/o family members has 
been extensively studied. In a D2-Gαi1 versus D2-
Gαo screening, we retrieved five agonists that are 
currently being used in antiparkinsonian 
medications. We determined that in this assay, 
piribedil and pergolide are full agonists for the 
recruitment of Gαi1 but are partial agonists for Gαo, 
that the agonist activity of ropinirole is biased in 
favor of Gαi1 recruitment, and that the agonist 
activity of apomorphine is biased for Gαo. We 
proposed that this newly developed assay could be 
used to develop molecules that selectively modulate 
a particular G protein pathway.  
G protein-coupled receptors (GPCRs) are a 
large family of membrane proteins that have pivotal 
functions in physiology and are directly targeted by 
more than 30% of our therapeutic arsenal (1). Given 
their successes in drug discovery, it is common 
sense to postulate that uncharacterized members 
hold great potential in terms of innovative 
therapeutic strategies (2-5). Several authors recently 
proposed that the paucity of adequate 
pharmacological tools was precluding research on 
elusive receptors (5, 6). In addition, there is still an 
unmet medical need in various diseases for drugs 
with improved properties such as increased potency, 
higher selectivity or refined efficacy for existing 
validated drug targets. Thus, the drug discovery 
process would benefit from more sophisticated 
assays able to detect with maximal accuracy the 
ligands with a desired pharmacological profile.  
GPCR signaling has been extensively studied 
and is notoriously complex. The current paradigm 
states that the binding of a ligand to its receptor 
stabilizes active conformations that in turn triggers 
through allosteric effects the formation of an active 
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complex bound with intracellular partners (7). It is 
generally accepted that the prime event following 
ligand binding is the interaction of the active 
receptor with heterotrimeric G proteins composed of 
α and βγ subunits (8). These elements dissociate 
upon activation and each of them has the capacity to 
promote distinct signaling pathways (9). Following 
G protein activation, the receptor undergoes 
desensitization and internalization through diverse 
processes involving phosphorylation by GPCR-
specific kinases (GRK) and scaffolding by proteins 
such as arrestins (10).  
In humans, the G protein family comprises 16 
members that are classified according to the identity 
of their α subunits into 4 families (11). Gαs family 
(Gαslong, Gαsshort, Gαolf) increases while Gαi/o family 
(Gαi1, Gαi2, Gαi3, Gαo, Gαz) decreases adenylate 
cyclase (AC) activity. Hence, Gαs/olf and Gαi/o 
oppositely regulate levels of cAMP in the cell (9). 
Gαq/11 family (Gαq, Gα11, Gα15, Gα16) triggers 
notably the activation of the Phospholipase C-β and 
calcium mobilization through the release of DAG 
and IP3 (9). Gα12/13 (Gα12 & Gα13) activate the small 
GTPases regulators Rho-GEF (9). Although 
individual receptors were initially seen as being 
selective for a given pathway and thus coupled to a 
single G protein, it has been observed that most 
receptors display at least some level of 
promiscuousness toward different G proteins or G 
protein families (9). Another layer of complexity 
exists in GPCR signaling with the observation of 
functional selectivity, which can be defined as the 
ability of a ligand to stabilize a specific receptor 
conformation leading to a unique and ligand-
determined profile of signaling pathways activation 
(7).  
A large array of pharmacological assays has 
been developed for the identification of substances 
able to modulate G proteins through GPCRs. Most 
of them focus on the downstream events triggered 
by G protein activation such as the generation of 
cAMP (Gαs/olf & Gαi/o) (12, 13), Ca2+ (14) and IP1 
(Gαq/11), downstream activation of gene promoters 
or more recently shedding of TGF-α (Gαq/11 & 
Gα12/13) (15). More generic and holistic assays 
measuring the accumulation of the non-hydrolysable 
GTP-γ-S (reflecting G protein activation) (16) or 
cell morphology (17) have also been extensively 
used. In order to extent the scope of an assay to 
more than one or two pathways, promiscuous G 
proteins linking most receptors to common second 
messengers are generally added to the system (18). 
Collectively, these assays are limited in the way that 
they cannot give direct information on the kind of G 
protein, or even on the identity of the GPCR, that 
has been activated by a given ligand. Thus, during 
screening campaigns, they are prone to deliver a 
high rate of false positives (13). 
More recent techniques based on resonance 
energy transfer (BRET and FRET) have given 
unprecedented access to the study of individual 
interaction between G protein and their receptors in 
living cells (19). However, these approaches suffer 
from important drawbacks such as limited 
sensitivity (BRET) or high background noise 
(FRET) that limit their use, for instance in high 
throughput screenings (20). In addition, they require 
the presence of bulky donor and/or acceptors, 
although reduced-size donors such as NanoLuc 
(BRET (21)) or FlasH (FRET (22)) are now 
routinely used.  
Here we describe a simple and flexible 
nanoluciferase (NanoLuc)-based complementation 
assay that overcomes these issues and gives access 
to the profiling of ligands for their ability to induce 
GPCR interaction with individual G protein. In 
addition, the procedure is compatible with the 
settings of high-throughput screening. We applied 
this methodology to several prototypical class A 
receptors and their cognate G proteins. The D2 
receptor is a well-validated drug target in psychosis 
and Parkinson’s diseases and is coupled to Gαi/o 
family. We used the D2 receptor as a proof-of-
concept to perform a screening of a library 
containing known drugs and active compounds 
against the D2 receptor.  
Results 
The NanoLuc Binary Technology system can 
monitor Receptor-G protein interaction in living 
cells 
In order to detect the real-time interaction 
between receptor and G proteins, we selected the 
NanoLuc Binary Technology (NanoBiT) that is 
based on NanoLuc, an engineered luciferase from 
the deep sea shrimp Oplophorus gracilirostris (23). 
We reasoned that the reported increased brightness 
of the enzyme would overcome sensitivity issues of 
other systems, such as firefly luciferase 
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expected the small size of the NanoBiT partners (a 
small subunit (SmBiT, 11 AA)) and a larger subunit 
((LgBiT, 158 AA), Fig. 1A (24)) could minimize 
perturbations of GPCR pharmacology that have 
been outlined with large fluorescent proteins (19). 
As a proof of concept for such approach, we 
first selected three receptors coupled to the Gαi/o 
family: the long isoform of the Dopamine receptor 
subtype 2 (D2) (25), the Histamine receptor H3 (26) 
and the Succinate receptor (SUCNR1) (27). The 
SmBiT was attached to the C terminus of the 
receptors and the LgBiT was introduced in the loop 
connecting helices A and B of the Gαi1 protein 
(Gαi1-LgB91) (Fig. 1A). The interaction between 
labeled receptor and Gαi1-LgB91 was estimated by 
measuring the emitted light upon agonist 
stimulation. All the tested receptors induced a rapid 
increase of luminescent signal upon stimulation 
(Fig. 2, A to C). However, the amplitude and 
stability of the obtained signal was relatively weak. 
We reasoned that the transient nature of the GPCR-
G protein interaction could, to some extent, explain 
the low level of the observed signal. SmBiT has 
been optimized to have a low affinity for LgBiT (KD 
= 190 µM (24)) compared to the native sequence 
(natural peptide or NP, KD =0.9 µM (24)) in order to 
minimize the perturbation of the physiological 
interaction induced by the presence of 
complementing partners (24). A third peptide with 
high affinity (HiBiT, KD=0.7 nM (24)) has also been 
described (Fig. 1B). In order to improve the signal-
to-noise ratio of our assay, we hypothesized that the 
affinity of the small complementing peptide could 
be a critical parameter for the sensitivity of the 
detection system. Therefore, we tested the other two 
peptides, NP and HiBiT fused at the same location 
than SmBiT on the test receptors. For the three 
receptors, the amplitude and the stability of the 
signal were markedly increased when NP was used 
as the complementation peptide (Fig. 2, D-F). For 
both these peptides, the signal remained stable for at 
least 10 minutes (Fig. 2, D to I), which is consistent 
with the literature describing real-time GPCR-G 
protein interaction (28, 29). 
Nanoluc complementation is completely reversible 
when natural peptide or SmBiT are fused to the 
receptor 
Next, we envisaged the possibility that the use 
of complementing partners with different affinities 
for each other could completely distort the GPCR-G 
protein interaction and increase the risk of detecting 
non-pharmacological interactions and the 
accumulation of irreversible receptor-G protein 
complexes. Thus, we tested the reversibility of the 
complementation between the three small peptides 
(SmBiT, NP and HiBiT) and LgBiT in our system. 
Following stimulation with dopamine, a competitive 
D2 receptor antagonist (Sulpiride) was injected. For 
the D2 receptor fused with the SmBiT, a rapid 
decrease of the NanoLuc signal that reached basal 
level was observed upon antagonist addition (Fig. 
3A). When the experiment was repeated with the 
constructs containing NP, a similar pattern was 
observed, although the signal-to-noise ratio was 
increased (Fig. 3B). When the HiBiT was used as a 
partner, the rate of dissociation was markedly 
decreased and the signal did not reach the basal 
level, suggesting an incomplete dissociation of the 
receptor-G protein complex (Fig. 3C). In light of 
such results we decided to select the system using 
the NP for further investigations. 
The GPCR-G protein NanoLuc complementation 
can be applied to all G protein subtypes 
We questioned the possibility of implementing 
the detection system to other G protein subtypes. 
Thus, we also expanded our detection system to 
other families of Gα proteins. We introduced the 
LgBiT in the loop connecting helices A and B of the 
other Gα proteins and tested the long isoform of Gαs 
with the β2 adrenergic receptor (β2AR) (Fig. 4A), 
Gαq and Gα11 with the histamine receptor H1 (H1) 
(Fig. 4B) and Gα12 and Gα13 with the thromboxane 
A2 receptor (TPα) (Fig. 4C). Upon stimulation with 
their respective ligands, a significant interaction 
between the receptor and the Gα subunit was 
recorded in cells co-transfected with β2AR-NP/Gαs-
LgB113, H1-NP/Gαq/11-LgB97and TPα-NP/Gα12/13-
LgB115/106 (Fig. 4, A to C). We then aimed at 
performing a complete profiling of G protein 
recruitment on a test receptor. We chose the well-
characterized D2 dopaminergic receptor as a model 
because it has been previously reported to couple 
differently to a diversity of G proteins from the Gαi/o 
family (30). We designed additional sensors for the 
other α subunits of the Gi/o family. We inserted the 
LgBiT at the same topological location in Gαi2 and 
Gαi3. For Gαo (the "a" isoform), the initial constructs 
gave poor signal and after different rounds of 
optimization the LgBiT was placed just after the 
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the N-terminal side (Gαo-LgB143d) was performed. 
We stimulated with dopamine HEK293 cells 
transiently transfected with D2-NP and each of these 
Gα subunits fused with LgBit. Exposure of D2-NP 
to its endogenous agonist, dopamine, induced a 
significant increase of luminescence signal when the 
receptor was co-expressed in HEK293 cells with 
either Gαi1-LgB91, Gαi2-LgB91, Gαi3-LgB91 or Gαo-
LgB143d but no activity when the D2-NP was co-
transfected with plasmids containing the validated 
constructs Gαs-LgB113, Gαq-LgB97, Gα11-LgB97, 
Gα12-LgB115 or Gα13-LgB106 (Fig. 4D). The 
interaction profile of the D2 with Gα subunits that 
was obtained with the present system was consistent 
with the ones already described in the literature (31-
33). 
The GPCR-G protein NanoLuc complementation 
system is amenable to high-throughput screening 
We further examined whether the GPCR-G 
protein NanoLuc complementation assay could be 
used for a high-throughput screening campaign. In 
order to transpose this assay to a screening protocol, 
we first optimized the Gαi1 construct. The LgBiT 
was inserted at different locations of the Gα protein 
and tested in presence of D2 receptor tagged with the 
NP (Fig. S1A). The LgBiT placed at the N terminus 
of Gαi1 (Gαi1-LgBN-term) showed the strongest signal 
among all the constructs tested. Similar 
investigations on Go confirmed that Gαo-LgB143d 
was the construct that gave the best signal-to-noise 
ratio (Fig. S1B). Next, we performed a flow 
cytometry experiment to determine the relative 
expression of the D2-NP receptor at the membrane 
compared to the intracellular expression of Gαi1-
LgBN-term and Gαo-LgB143d in transiently transfected 
HEK293 cells. We observed similar expression of 
receptor and Gα protein constructs for the two 
conditions of transfection (Fig. S2). In order to 
obtain the higher signal-to-noise ratio, we tested 
different stoichiometry of D2-NP and Gαi1-LgBN-term/ 
Gαo-LgB143d for the transfection. A ratio 1:1 of 
receptor and Gα subunit revealed a higher signal-to-
noise ratio and was used for the subsequent 
experiments (Fig. S3A). Next, we reasoned that the 
Gβγ dimer could affect the amplitude of the signal 
obtained, as it has been shown for the RET-based 
systems (28). However, the coexpression of Gαo-
LgB143d with its complementary Gβ1γ2 dimer did not 
modify the recruitment of Gαo-LgB143d to D2-NP. 
Interestingly, the coexpression of D2-NP and Gαi1-
LgBN-term with Gβ1γ2 subunits decreased the signal 
of NanoLuc complementation upon dopamine 
stimulation, while it did not affect the pEC50 (Fig. 
S3B). Thus, the detection of the interaction between 
NP-tagged GPCR and the LgBiT-tagged Gα subunit 
does not require the coexpression with the Gβγ 
dimer. 
Concentration-response curves that were 
determined on the system revealed specific 
interaction between D2-NP/Gαi1-LgBN-term (EC50 = 2 
nM) and D2-NP/ Gαo-LgB143d (EC50 = 116 nM) in 
the presence of dopamine (Fig. 5, A and B). During 
the kinetic measurement of the D2-NP/Gαi1-LgBN-
term or the D2-NP/ Gαo-LgB143d interaction induced 
by dopamine stimulation, we observed an increase 
of signal that started to decrease immediately upon 
competitive antagonist (Sulpiride and Spiperone) 
addition (Fig. 5, C and D). The affinity of Sulpiride 
for the D2-NP construct that was estimated with a 
Schild plot (Fig. S4) was not significantly different 
between the two assays and was consistent with the 
literature (34). We applied statistical methods to 
determine if this assay would be suitable for high-
throughput screening. We calculated the Z’ factor 
which includes the mean and the standard deviation 
of the positive and negative control (35). This factor 
reflects the dynamic range of the assay and its 
ability to detect active ligands. A Z’ factor that is 
comprised between 0.5 and 1 is characterized by a 
large band separation between positive and negative 
signals and can be considered as an excellent assay 
for hit identification (35). When cells co-expressing 
D2-NP with Gαi1-LgBN-term or Gαo-LgB143d were 
stimulated with either dopamine or the vehicle in a 
96 well-plate, the Z’ factors were of 0.61 and 0.69, 
respectively (Fig. 5, E and F). 
Gα i1- and Gαo-based screening of a SOSA library 
identifies D2 agonists with distinct 
pharmacological profiles 
To further validate our approach, we screened a 
SOSA library composed of 1200 known active 
compounds and drugs (Prestwick chemical library®) 
on D2-NP expressing cells together with the Gαi1- or 
Gαo-based complementation constructs (Gαi1-LgBN-
term or Gαo-LgB143d) in parallel. Several agonists of 
the D2 receptor were present in this library and we 
reasoned that they would serve as internal positive 
controls. We fixed the threshold for hit 
identification as the mean of the negative control 
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criterion, we detected the six agonists (the D2 
agonists were listed according to the BJP/IUPHAR 
database http://www.guidetopharmacology.org) of 
the D2 receptor present in the library (Fig. 6, A and 
B).  
Next, we tested a wide range of agonist 
concentrations and compared the profile of each 
ligand with regard to dopamine that was defined as 
the reference ligand. Surprisingly, the pEC50 of 
dopamine was very different between the Gαi1 and 
Gαo-based interaction assay (Table 1; pEC50: 8.64 ± 
0.10 and 6.60 ± 0.05, respectively). We postulated 
that the difference between pEC50 could be the 
consequence of using different constructs. Actually, 
when we tested several constructs of Gαi1-LgB, we 
also obtained a difference of pEC50 upon stimulation 
with dopamine (Fig. S1).  
We compared all data obtained with both Gαi1 
and Gαo assays relatively to dopamine. We observed 
that the Emax of the D2 agonists were similar when 
we measured the interaction between D2-NP and 
Gαi1-LgBN-term (Table 1). However, when cells 
expressing D2-NP and Gαo-LgB143d were stimulated 
with apomorphine, piribedil and pramipexole, we 
detected lower efficacies compared to the one of 
dopamine as these compounds behaved as partial 
agonist for the initiation of interaction between D2 
and Gαo. For example, piribedil exhibited a decrease 
of efficacy up to 3-fold in comparison to the one 
measured for dopamine (Fig. 7, A and B). 
Furthermore, although pergolide was more potent 
than dopamine as an inducer of both the D2-
NP/Gαi1-LgBN-term and D2-NP/Gαo-LgB143d 
interactions (Table 1; pEC50 of 10.13 ± 0.07 and 
8.26 ± 0.07 for Gαi1-LgBN-term and Gαo-LgB143d, 
respectively), we observed a lower efficacy for 
pergolide when measuring the interaction between 
D2-NP and Gαo-LgB143d. Ropinirole-promoted D2-
NP/Gαi1-LgBN-term and D2-NP/Gαo-LgB143d 
interactions were both less potent compared to 
dopamine (Fig. 7, A and B). In addition, relatively 
to dopamine, ropinirole showed a higher potency for 
inducing the D2-NP/Gαi1-LgBN-term compared to the 
D2-NP/Gαo-LgB143d interaction (Table 1; pEC50 of 
8.23 ± 0.06 and 5.89 ± 0.08 for Gαi1 and Gαo, 
respectively). 
For the different tested ligands, there were no 
marked differences (when compared with 
dopamine) between the pEC50 for D2-NP and Gαi1-
LgBN-term or D2-NP and Gαo-LgB143d interactions 
(Fig. 7C). However, when we considered the Emax, 
partial agonism was recorded when measuring the 
interaction between D2-NP and Gαo-LgB143d (Fig. 
7D). This difference in measured Emax was more 
notable for piribedil and pergolide (Fig. 7D). For 
each tested ligand, ∆log(Emax/EC50) was determined 
for both Gα constructs using dopamine as the 
reference ligand, followed by the calculation of the 
bias factor as ∆∆log(Emax/EC50) (∆log(Emax/EC50)Gαi1 
pathway - ∆log(Emax/EC50)Gαo pathway) according to 
previously described method (36). A bias factor of 0 
corresponds to absence of bias (relative to the 
reference ligand, dopamine), whereas a bias factor 
of 1 would means a 10-fold preference for inducing 
the Gαi1 interaction. In opposite, a negative value 
would mean a preference for the Gαo-dependent 
pathway. A bias factor of -0.27 (± 0.03) 
(apomorphine), -0.12 (±0.18) (piribedil), 0.04 (± 
0.17) (pramipexole), 0.41 (± 0.12) (ropinirole) and 
0.09 (± 0.18) (pergolide) was computed for D2 
agonists, demonstrating a significant bias for 
ropinirole and apomorphine through Gαi1-LgBN-term 
and Gαo-LgB143d, respectively (Fig. 7E). Thus, the 
GPCR-G protein NanoLuc complementation assay 
is able to identify biased agonists for certain G 
proteins.  
Furthermore, we tested the possibility of an 
extension of this assay to detect β-arrestin 
recruitment. Thus, we also evaluated these five D2 
agonists using dopamine as reference ligand in a β-
arrestin 2-based NanoLuc complementation assay. 
We observed a partial activity for apomorphine, 
piribedil, ropinirole and pergolide, while 
pramipexole was a full agonist for β-arrestin 2 
recruitment (Fig. S5). This assay was based on the 
same D2-NP construct and a β-arrestin 2 tagged with 
the LgBiT at the N terminus. Thereby, we were able 
to monitor G protein or β-arrestin interaction using 
the same readout.  
Discussion 
In this study, our first goal was to develop a 
simple, robust and sensitive GPCR assay for the 
real-time detection of receptor-G protein interaction 
that would be amenable to high throughput 
screening. 
The protein-fragment complementation assays 
have been devised on the principle that two 
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two putative partners would be detectable upon 
interaction (37). These strategies have greatly 
advanced our understanding of cellular biology, 
molecular biology or pharmacology. However, 
although they have a relatively high signal-to-noise 
ratio, they have been so far less popular compared to 
RET to monitor GPCR-G protein interactions. The 
main reason for this is that the complementation 
may perturb the natural interaction between the 
partners under scrutiny because of a possible 
intrinsic affinity between the two split parts of the 
reporter proteins or the irreversibility of the 
complementation once formed. For example, 
systems based on fluorescent protein of the GFP 
family or some β-galactosidase are unable to 
dissociate once re-formed and accumulate in the 
system (38). The Firefly and Gaussia luciferases 
seem to have a reduced propensity to form stable 
complexes but the split parts have affinity for each 
other and once reformed they are not very bright (39, 
40). 
Recently, a novel protein fragment 
complementation based on a brighter and smaller 
luciferase called NanoLuc has been described (24) 
and was already applied in the GPCR field to detect 
receptor-arrestin association (24, 39, 41). NanoLuc-
based complementation presents several advantages 
compared to other RET- or complementation-based 
techniques. First of all, the system does not suffer 
from sensitivity issues because the protein that 
detects the interaction is a brighter luciferase (42). A 
second improvement is the small size of both the 
reconstituted luciferase and one of the 
complementing partners (13 AA only for the 
SmBiT, 11 AA for NP) that minimizes the risk for 
artefacts that would be induced by the bulky nature 
of the system constituents (24). A third advantage 
that we noticed is the dynamic reversibility of the 
system, at least when the SmBiT and NP were used 
on H3, D2 and SUCNR1 (see Fig. 3B and Fig. 5 
C&D). It is important to note that we did not 
formally demonstrate that the true dynamic of 
GPCR-G protein interaction was preserved. 
Therefore, we cannot exclude that the rate of 
association/dissociation is impaired as a 
consequence of the complementation. 
Notwithstanding, the basal affinity of the 
complementing partners could still promote 
artefactual constitutive activity by bringing the G 
protein and the receptor in close vicinity. However, 
this assay was not designed to study these dynamics 
but to detect active ligands for uncharacterized 
receptors. Thus, the possible increase of sensitivity 
may actually be seen as beneficial.  
Several strategies have been successfully 
applied in the past to specifically monitor the G 
protein that interacted with or was activated by a 
receptor bound by an agonist. Historically, the first 
reported attempts used cellular backgrounds such as 
the yeast or insect cells that are devoid of most of 
the G proteins or GPCR present in human cell lines 
such as HEK293 (43). Another screening-
compatible assay that is able to monitor the 
activation of each G protein individually has been 
described recently (33). This elegant approach 
detects the interaction of the activated G protein 
(Gβγ subunits) with GRK3 with a NanoBRET 
system and was applied to profile the coupling 
between receptors and a large set of G proteins (33). 
Our approach differs in several aspects compared to 
the one described by Masuho et al. First, some G 
proteins, such as Gα12, were not detectable by their 
system (33). Secondly, although the sensitivity and 
signal-to-noise ratio is relatively high, the authors 
did not test the possibility of using that assay for a 
screening campaign. Thirdly, the nature of the 
activating receptor giving rise to the recorded signal 
is not identifiable in a system solely based on G 
protein activation. Thus, a screening campaign on an 
elusive receptor with the assay described by Masuho 
et al. would give a high rate of false positive ligands 
that are activating the endogenous GPCRs present 
on the cell surface. Another putative way to monitor 
single G protein interaction to a receptor was 
published during the preparation of this manuscript. 
Using G proteins truncated at their N-terminal parts 
that were initially developed to facilitate 
crystallographic studies (called mini G protein), 
Wan et al. reported that they could monitor G 
protein-GPCR interactions but did not challenge the 
assay in screening conditions (44). Interestingly, we 
applied independently a reduction of the size of G 
protein to optimize our Gαo construct, further 
validating this strategy to improve the performance 
of engineered G proteins. Actually, all the constructs 
we developed did not give the same results in terms 
of sensitivity or signal-to-noise ratio. It should be 
taken into account when implementing the system 
for other receptors that several constructs should be 
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particular importance for orphan receptors were the 
confidence in assay performance is critical if no 
positive control exists.  
BRET and FRET approaches have been 
extensively used to monitor G protein recruitment. 
In principle, a donor (a luciferase in the case of 
BRET or fluorescent protein in the case of FRET) is 
fused to one of the interacting partners and an 
acceptor fused to another. In case of sufficient 
proximity (the donor and acceptor must be at a 
distance below 10Å with a correct orientation (19)), 
the fluorescence of the acceptor can be detected at a 
unique wavelength while the recorded emission of 
the donor will be reduced (19). Although these 
elegant RET approaches shed light on exquisite 
aspects of receptors pharmacology such as G 
protein-GPCR association/dissociation rate or G 
protein recruitment fingerprints for individual 
ligands (29, 45, 46). They were never applied to 
library screenings probably because of their limited 
sensitivity. In addition, it should be noted that for 
RET systems to work, the presence of Gβγ is 
required with precise stoichiometry, which further 
limit their broad use, especially for screening 
campaigns. Here, we have demonstrated that the 
NanoLuc complementation applied to Gα does not 
necessitate the co-transfection of additional Gβγ 
subunits (Fig. S3B). For the ease of comparison, we 
have listed in the table 2 the advantages and 
limitations of different methods available to monitor 
G protein-GPCR interactions in living cells. 
The dopaminergic system is composed of 5 
dopamine receptors (D1 & D5 principally coupled to 
Gαs/olf and D2-4 coupled mainly to Gαi/o family) of 
which several are validated therapeutic target for 
debilitating conditions such as Parkinson’s disease 
(PD) or psychotic disorders (30). PD is a 
degenerative disorder marked by tremor, rigidity 
and slowness of movement due to a decline of 
dopaminergic neurons in the substantia nigra (47). 
In general, the dopaminergic drugs used to treat PD 
aim at restoring dopamine signalling in affected 
areas such as the striatum, notably through the 
activation of the receptor from the D2 family (48). 
The screening of a library of known drugs on the D2 
receptor with a novel GPCR-G protein interaction 
assay detected five D2 receptor agonists that are 
currently in use to treat patient suffering from PD 
(49). The full concentration-response curves that we 
determined for D2-Gαi1 and -Gαo interaction showed 
that while there were no relative differences 
(compared to dopamine) with regard to the 
potencies of the agonists (except for ropinirole), 
their Emax displayed signs of partial agonism when 
recruiting Gαo, in particular for piribedil and 
pergolide (see Fig. 7 and Table 1). The bias factors 
that we calculated indicate a different 
pharmacological profile for the different 
compounds, especially Ropinirole and 
Apomorphine. At this stage, the demonstration that 
the partial agonism on Gαo is linked to the 
therapeutic effect would be premature but the assay 
presented here has the potential to facilitate the 
discovery of compounds with a more pronounced 
bias that could be evaluated for a beneficial 
therapeutic effect.  
Furthermore, the difference in pharmacological 
profile we observed between Gαi1 and Gαo with the 
NanoLuc complementation on D2 agonist are 
consistent with the literature. Pioneering work by 
the Strange lab in insect cells demonstrated that 
different agonists had the ability to elicit different 
responses depending on the G protein subtype (32, 
50). Using G protein mutants resistant to PTX 
treatment, Milligan and his team managed to 
evidence similar behaviour of the D2 receptor toward 
different G proteins of the Gαi/o family (31).  
The current approaches to detect biased 
agonism are focused on the differences between G 
proteins and arrestins, were the assays to detect 
pharmacological parameters are, respectively, the 
measurement of second messengers and a 
complementation assay between arrestin and the 
active receptor (51). However, we think that it 
would be preferable to estimate bias with a common 
strategy instead of different assays because the 
assays are an important source of artefacts when 
determining bias. We demonstrated here that the 
nanoluciferase complementation could also be 
applied to the estimation of the arrestin recruitment 
(Fig. S5). Thus, a NanoLuc complementation can be 
applied to a more robust analysis of biased agonism 
between arrestin (or any other intracellular partner, 
in theory) and a given G protein.  
In conclusion, the present study describes the 
development and usefulness of a novel system for 
the detection of direct interactions between GPCR 
and single G protein. This assay has a dynamic 
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screening. It opens new avenues for programs 
aiming at the identification in large libraries and 
optimization of original scaffolds characterized by 
biased agonism at the level of G protein subtype, a 
feature that would be impractical with current 
technologies. Exquisite pharmacological tools such 
as biased agonists selectively promoting the 
interaction of a receptor with a restricted set of G 
proteins should ease our understanding of the 
physiological rationale for multiple coupling and 
apparently redundant G proteins. 
Experimental Procedures 
Materials  
Dopamine, isoproterenol, succinate, histamine, 
imetit, sulpiride, piribedil, pramipexole and 
pergolide were from Sigma-Aldrich (St. Louis, 
MO). Ropinirole and U46619 were from Santa Cruz 
(Dallas, Texas, USA); spiperone from Abcam 
(Cambridge, UK). Prestwick Chemical Library® was 
from Prestwick Chemical (Illkirch, France). 
Plasmids  
Human D2 Long, Gαi2 and Gαi3 were amplified 
from human ORFeome (version 7.1, 
http://horfdb.dfci.harvard.edu/hv7/). Human H1, H3, 
TPα, Gαoa and Gαs were amplified from pcDNA3.1+ 
coding for each protein (cDNA Resource Center, 
Bloomsburg, PA). SUCNR1 coding sequence was 
amplified from genomic DNA of human embryonic 
kidney 293 (HEK293) cells. β2AR, Gαi1, Gαq, Gα11, 
Gα12 and Gα13 were amplified from complementary 
DNA (cDNA) of HEK293 cells mRNA. All 
receptors were cloned into the pcDNA3.1+ 
(Invitrogen, Carlsbad, CA) after addition of the Flag 
epitope (DYKDDDDK) at the N terminus, preceded 
by the signal sequence KTIIALSYIFCLVFA (Guan 
et al., 1992) for D2 and β2AR. After cloning into the 
pcDNA3.1+, the SmBiT (VTGYRLFEEIL), NP 
(GVTGWRLCERILA) and HiBiT 
(VSGWRLFKKIS) were added with a flexible 
linker (GNSGSSGGGGSGGGGSSG) in frame to 
the C terminus of the receptor by polymerase chain 
reaction (PCR). All G proteins were cloned into the 
pcDNA3.1+ (Invitrogen, Carlsbad, CA) after 
addition of the HA (YPYDVPDYA) epitope at the 
N terminus. Then, EcoRV and SacII sites (except 
BamHI and SacII for Gα12) were inserted by PCR 
between specific amino acid residues of the Gα 
protein in order to insert the LgBiT. The coding 






was amplified by PCR and inserted, flanked by a 
flexible linker (SGGGGS) and the respective 
restriction sites, into the Gα subunit sequence. The 
location of the LgBiT was topologically identical for 
each of the following Gα subunits: between residues 
91 and 92 of Gαi (Gαi1-LgB91, Gαi2-LgB91, Gαi3-
LgB91) and Gαoa (Gαo-LgB91), residues 97 and 98 of 
Gαq/11 (Gαq-LgB97 and Gα11-LgB97), residues 113 
and 114 of Gαs (Gαs-LgB113), residues 115 and 116 
of Gα12 (Gα12-LgB115) or residues 106 and 107 of 
Gα13 (Gα13-LgB106). The Gαi1 constructs used for the 
screening has been obtained as followed: the LgBiT 
was added at the N terminus of Gαi1 by cloning its 
coding sequence into the pNBe3 vector (Promega 
Corporation, Madison, WI, USA) with XhoI and 
SacI sites and a HA tag was added at the C terminus 
sequence by PCR (Gαi1-LgBN-term). The Gαoa 
construct used for the screening was obtained by 
insertion of the LgBiT, flanked by a flexible linker 
(SGGGGS) and EcoRV/SacII sites, between 
residues 143 and 144 of Gαoa with a HA tag at the N 
terminus cloned into the pcDNA3.1+ (Invitrogen, 
Carlsbad, CA). Then, the deletion of the first 52 
amino acids was performed using the Q5 Site-
Directed Mutagenesis Kit (New England Biolabs, 
Massachusetts, USA) (Gαo-LgB143d). For the β-
arrestin 2-based NanoLuc complementation assay, 
β-arrestin 2 was cloned into pNBe3 vector (Promega 
Corporation, Madison, WI, USA) with XhoI and 
EcoRI sites. All constructs were verified by 
sequencing. 
Cell Culture and Transfection  
HEK293 cells were from American Type 
Culture Collection (Manassas, VA) and grown in 
Dulbecco’s modified Eagle medium (Lonza, 
Verviers, Belgium) containing 10% fetal bovine 
serum (International Medical Products, Brussels, 
Belgium), 1% penicillin/streptomycin (Lonza), and 
1% L-glutamine (Lonza) at 37°C with 5% CO2. At 
80% confluency, cells were transfected with 
XtremeGene 9 (Promega Corporation, Madison, WI, 
USA) in a 3:1 (reagent:DNA) ratio according to the 
manufacturer’s recommendations. A 1:1 ratio 
(GPCR:G alpha subunit) was used with a solution of 
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Measurement of GPCR-G protein interaction by 
NanoLuc complementation assay  
Twenty-four hours after transfection of 
HEK293 cells with a 1:1 ratio of GPCR and Gα 
subunit plasmid solutions diluted 1/10 with empty 
pcDNA3.1+, cells were detached from 20 or 55 cm2 
dishes with trypsin. After one wash with PBS, cells 
were resuspended into Hanks’ balanced salt solution 
(HBSS; 120 mM NaCl, 5.4 mM KCl, 0.8 mM 
MgSO4, 10 mM HEPES, pH 7.4) supplemented 
with the NanoLuc substrate (Promega Corporation, 
Madison, WI, USA), seeded into a white 96-well 
plate (50,000 cells/well) and incubated for 45 
minutes at 37°C. Cells were stimulated by adding 1 
µl of 100x ligand solutions and luminescence was 
recorded for several minutes depending on each 
experiment (Centro XS3 LB960; Berthold 
Technologies). The same protocol was used for β-
arrestin 2 recruitment after a transient transfection of 
receptor and β-arrestin 2-encoding plasmids diluted 
1/10 with empty pcDNA3.1+ into HEK293 cells in a 
1:1 ratio. 
 To determine the Z’ factor, cells co-transfected with 
D2-NP and Gαi1-LgBN-term or D2-NP and Gαo-LgB143d 
were resuspended into HBSS supplemented with 
NanoLuc substrate and seeded in a white 96-well 
plate (50, 000 cells/well) at 37°C for 45 min. Half of 
the plate was stimulated with vehicle and the other 
half with dopamine 100x concentrated and the 
luminescence was recorded for 10 min. The 
screening of the Prestwick Chemical Library® was 
performed at 5 µM on HEK293 transiently 
transfected with the pair of D2-NPand Gαi1-LgBN-term  
or Gαo-LgB143d (1:1 ratio with a solution of plasmids 
diluted 1/10 with empty pcDNA3.1+). The cells 
were detached in parallel for Gαi1 and Gαo, 
resuspended into HBSS supplemented with the 
NanoLuc substrate (Promega Corporation, Madison, 
WI, USA) and incubated for 45 min at 37°C. Then, 
the compounds of the library (dissolved in dimethyl 
sulfoxide) were added into D2-Gαi1 plate and 
luminescence was recorded for 10 min. After, the 
compounds of the same plate of the library were 
added to D2-Gαo plate and luminescence was 
recorded for 10 min. 
Data Analysis and Hit Selection Criteria  
All data show a representative result from 3 
independent experiments, except data from Fig. 4 
which represent the mean ± S.D. of 3 independent 
experiments. Data were collected as RLU during 10 
min after stimulation and the areas under the curve 
were calculated and then normalized to the vehicle, 
considered as 0% activity. Statistical significance of 
the NanoLuc activity in presence of ligand from 
basal activity was assessed using nonparametric, 
Mann-Whitney test (***, P < 0,001). Concentration-
response curves were fitted to the four-parameter 
Hill equation using the least-squares method 
(GraphPad Prism, version 5.0 for Windows; 
GraphPad, La Jolla, CA). To combine the results 
obtained for all tested ligands, we considered the 
Emax of dopamine as equal to 100% and represented 
the activity of each ligand compared to the activity 
of dopamine.  
The Z’ factor was calculated as follows: Z'= 1-
((3σc+ + 3 σc-)/|µc+ - µc-|), where σ, represents the 
standard deviation; µ, the mean; c+, positive control; 
c- negative control. For the screening of the 
Prestwick Chemical Library® compounds were 
considered as hits when the ratio > (mean ratio(VEH) 
+ 3 S.D.(VEH)). Ratio represents 
RLU(compound)/RLU(VEH). Bias factor was calculated in 
two steps. First, we determined the ∆log(Emax/EC50) 
for Gαi1 and Gαo pathway which represents the 
difference between D2 agonist values and dopamine 
values used as reference ligand obtained with the 
Gαi1- and Gαo-based assay. Then, the bias factor 
corresponding to ∆∆log(Emax/EC50) was calculated 
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GPCR: G protein-coupled receptors 
GRK: GPCR kinase 
AC: Adenylate cyclase 
cAMP: Cyclic adenosine monophosphate  
DAG: Diacylglycerol  
IP3: Inositol triphosphate  
GEF: Guanine nucleotide exchange factor  
D2: long isoform of the Dopamine receptor 2 
NanoBiT: NanoLuciferase Binary Technology 
BRET: Bioluminescence resonance energy transfer  
FRET: Fluorescence resonance energy transfer  
LgB, Large BiT 
H3: Histamine receptor 3 
SUCNR1: Succinate receptor 
NP: Natural peptide 
NanoLuc: Nanoluciferase 
β2AR: β2 adrenergic receptor 
H1: histamine receptor 1 
TPα: Thromboxane A2 receptor α 
RLU: Relative luminescence units 
SD: Standard deviation 
SEM: Standard error of the mean  
IP1: Inositol monophosphate 
TGF-α: Transforming growth factor α  
RET: Resonance energy transfer 
GFP: Green fluorescent protein 
PD: Parkinson’s disease 
PTX: Pertussis toxin  
RAMPS: Receptor activity-modifying proteins 
RGS: Regulators of G-protein signalling 
GASPs: GPCR-associated sorting proteins 
PDZ: PSD95/Disc Large/Zona Occludens 
SH3: Src homology 3 
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Table 1. Agonist activity on Gαi1 and Gαo interaction of D2 ligands 	 	 Gi1 Go Bias	factor 









(Std	Error) Dopamine 8.64	(0.10) 100 6.60	(0.05) 100 0	(0.12) Apomorphine 8.25	(0.04) 103 6.62	(0.04) 63 -0.27	(0.03) Piribedil 8.28	(0.04) 112 6.76	(0.14) 42 -0.12	(0.18) Pramipexole 8.59	(0.07) 119 6.80	(0.09) 77 0.04	(0.17) Ropinirole 8.23	(0.06) 106 5.89	(0.08) 73 0.41	(0.12) Pergolide 10.13	(0.07) 100 8.26	(0.07) 54 0.09	(0.18) 
 
Agonist-induced Gαi1 or Gαo interaction with D2. Efficacy (Emax) relative to the maximum effect of 
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Table 2. Reported techniques for the real-time profiling of GPCR-G protein coupling 
Technique Design Advantages Limitations Amenable 
to HTS 
references 
FRET CFP and YFP 
variants 
- Labelling possible on 
intra- and extracellular 
side 
- No perturbation of the 
natural interaction 
- Excitation and 
emission cross-talk 
- High background 
(Autofluore-scence) 
- Large size of the 
fluorescent proteins 
(27 KDa) 
- Addition of Gβγ 
dimer 
No (19,	29) 
BRET RLuc and 
GFP variants 
- No perturbation of the 
natural interaction 
- No excitation by an 
external light source 




- large size (27 kDa) 








- improved signal 
compared to BRET 
- greater light output 
- Medium size of 
NanoLuc (19kDa) 
- no tagged-receptor 
or Gα subunit 
- Large size of the 
venus (27kDa) 










- brighter than BRET 
methods 
- low background 
- Small size of the 
SmBiT (1.3 kDa) 
- Medium size of 
LgBiT (18 kDa) 
 
 
- non ideal emission 
for in vivo 
applications 
- modified G 
proteins 





















- brighter than BRET 
methods 
- high signal-to-noise 
ratio 
- low background 
- Medium size of the 
complementing 
partners (~9.5 kDa 
each) 
 
- non ideal emission 
for in vivo 
applications 





NP (1-13) and 
LgBiT (14-
171) 
- brighter than BRET 
methods 
- high signal-to-noise 
ratio 
- low background 
- Small size of the NP 
(1.5 kDa) 
- Medium size of 
LgBiT (18 kDa) 
 
- non ideal emission 
for in vivo 
applications 
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Figure Legends 
Figure 1. NanoLuc complementation system. (A) Constructs for the NanoLuc complementation assay 
between a GPCR linked to SmBiT, NP or HiBiT peptides and a Gα subunit linked to LgBiT. Upon 
stimulation (yellow circle), the coupling of heterotrimeric G protein to the receptor triggers the exchange of 
a GDP (purple star) by a GTP (green star) followed by dissociation of Gα from Gβγ subunits. The 
interaction between GPCR and Gα subunit induces the formation of a complete NanoLuciferase and light 
emission in the presence of its substrate. (B) Amino acid sequence and KD of the different small peptides 
(SmBiT, NP and HiBiT). Red amino acids represent mutated amino acids compared to NP. 
Figure 2. NanoLuc complementation measurement of interaction between Gαi1 and GPCRs linked to 
SmBiT, NP or HiBiT peptides in living cells. NanoLuc activity kinetics measured in HEK293 cells 
coexpessing Gαi1-LgB91 and GPCRs linked to three different small peptides indicated in each panel. (A, B 
and C) D2, H3 and SUCNR1 linked to SmBiT; (D, E and F) D2, H3 and SUCNR1 linked to NP; (G, H and I) 
D2, H3 and SUCNR1 linked to HiBiT, before and after injection of their respective ligand (dopamine 1 µM, 
imetit 100 nM and succinate 1 mM). Results are expressed as the normalization of the NanoLuc signal in 
presence of agonist to the signal in absence of agonist. Data are representative of the mean ± S.E.M. of at 
least 3 independent experiments. 
Figure 3. Reversibility of the SmBiT, NP and HiBiT peptides. NanoLuc activity was measured in 
HEK293 cells coexpessing Gαi1-LgB91 and D2 linked to SmBiT (A), NP (B) or HiBiT (C), before and after 
stimulation with the receptor ligand dopamine (1 µM). Twenty minutes after addition of agonist, a 
selective-receptor antagonist sulpiride (10 µM) was injected. Data represent stimulated cells normalized to 
non-stimulated cells. Data are representative of the mean ± S.E.M. of at least 3 independent experiments.  
Figure 4. NanoLuc complementation measurement of GPCR and G protein interactions in living 
cells. (A-D) NanoLuc activity was measured in HEK293 cells coexpressing G alpha subunit linked to 
LgBiT and GPCR linked to NP as indicated in each panel. Cells were stimulated with vehicle or with their 
respective agonist (isoproterenol, histamine, dopamine 10 µM; U46619 10 nM) and the results are 
expressed as the normalization of agonist-treated cells to untreated cells. Data represent the mean ± S.D. of 
three independent experiments performed in triplicate. Statistical significance between stimulated and 
unstimulated cells was assessed using a nonparametric Mann-Whitney test (***, P < 0.001). 
Figure 5. Screening compatible NanoLuc complementation assay for GPCR and G protein 
interactions. HEK293 cells coexpressing D2-NP/Gαi1-LgBN-term or Gαo-LgB143d. (A-B) Concentration-
response curves of dopamine. (C-D) Kinetic measurements of NanoLuc activity during stimulation with 
dopamine and after addition of two different antagonists (sulpiride and spiperone). (E-F) Assay 
performance (Z’ factor determination) for D2 untreated and treated with dopamine (10 µM) on transiently 
cotransfected cells (n = 48). Data are representative of at least 3 independent experiments. 
Figure 6. Screening of Prestwick chemical library® on D2-Gαi1 and D2-Gαo. (A-B) 1200 compounds 
were tested at the same concentration (5 µM) on cells coexpressing D2-NP/Gαi1-LgBN-term or Gαo-LgB143d. 
Results are expressed as the ratio over vehicle (DMSO)-treated (compounds) cells. 
Figure 7. Pharmacological characterization of D2 agonists on Gαi1 and Gαo coupling. (A-B) 
Concentration-response curves of five D2 agonists on Gαi1 and Gαo interaction. Emax is expressed as the 
percentage of dopamine maximal activity. Estimation of pEC50 values (± S.D.) for each ligand and agonist 
efficacy measurements relative to dopamine are provided in table 1. Correlation between the pEC50 (± S.D.) 
(C) and Emax (± S.D.) (D) values determined in Gαi1 and Gαo assays. (E) Bias factors [ΔΔlog(Emax/EC50)] 
(± S.D.) calculated for tested D2 agonists; positive values indicate bias for Gαi1- over Gαo-dependent 
pathway, while negative values indicate bias for Gαo-dependent pathway. Unpaired Student’s t tests were 
performed on the bias factors to determine the significance of ligand biases between Gαi1 and Gαo 

















SmBiT - V T G Y R L F E E I L - 1.9 x 10- 4
Natural peptide G V T G W R L C E R I L A 0.9 x 10- 6

























Dopamine 1 µM Dopamine 1 µM Dopamine 1 µM
Imetit 100 nM Imetit 100 nM Imetit 100 nM
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Z’ factor = 0.61
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